IMTX - Immatics N.V.
3.52
-0.160 -4.545%
Share volume: 1,186,103
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.07%
PREVIOUS CLOSE
CHG
CHG%
$3.68
-0.16
-0.04%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
0.57%
1 Month
-21.78%
3 Months
-45.26%
6 Months
-68.20%
1 Year
-68.12%
2 Year
-41.91%
Key data
Stock price
$3.52
DAY RANGE
$3.45 - $3.88
52 WEEK RANGE
$3.30 - $13.77
52 WEEK CHANGE
-$68.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
Company detail
CEO: Harpreet Singh-Jasuja
Region: US
Website: immatics.com
Employees: 260
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: immatics.com
Employees: 260
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Immatics N.V. focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited.
Recent news
